Vivos Inc Updates Human Therapy Progress in India

Core Insights - Vivos Inc. has provided a positive update regarding ongoing human therapy demonstrations in India using RadioGel Precision Radionuclide Therapy, initiated in December 2024 [1] Group 1: Patient Outcomes - Patients have been attending regulatory follow-up visits as per protocol, with no serious adverse events reported to date [2] - Some patients have shown tumor size reduction over short intervals, with no recurrence noted during the follow-up period [3] - The therapy has been evaluated in cases involving tumors near critical structures, with no damage to adjacent organs reported [3] Group 2: Regulatory and Clinical Development - The company is working towards obtaining DCGI regulatory clearance later this quarter to expand the therapy phase, which will include enhanced protocols based on prior FDA interactions [4] - A therapist and facility have been selected for a larger-scale clinical trial to support future regulatory and commercial pathways in India [5] - Vivos Inc. is committed to submitting comprehensive results from the India demonstrations as part of its efforts to share scientific insights with the medical community [6] Group 3: Product Development Focus - Vivos Inc. remains focused on the development of RadioGel as a targeted therapy option for solid tumors, with ongoing support from shareholders [7]